obesity drug news today october 2025 glp-1 Outlook for in 2025: more than a transition year Obesity GLP-1 Market Size to

The most prevalent factors employers take into consideration for GLP-1 drug coverage for obesity care include: Obesity as a risk factor for chronic conditions and associated costs67% Drug shortages47% Impact/effectiveness of cost-control mechanisms47% Existing coverage through government programs40% Long-term costs33% Patient and prescriber demand33%

J Clin Diagn Res

Move GLP-1s to the Pharmacy Benefit Many GLP-1s administered in a clinical setting are billed under the medical benefit, where visibility and control are limited

Insulin Glargine in Combination with Metformin and Glimepiride in T2D Patients)94), 0.75- and 1.5-mg doses of once-weekly dulaglutide were compared with a 1.5-mg dose of insulin glargine, titrated to target a fasting blood glucose level around 100 mg/dL, based on metformin treatment

The point is not that you should be able to read all the side-effects, but rather impress upon you that all medications have potential side effects, and many have lots of them

ITT, Insulin tolerance test